Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Advances in diabetes for the millennium: drug therapy of type 2 diabetes.

Literature DB >> 15647714

Advances in diabetes for the millennium: drug therapy of type 2 diabetes.

Abstract

There are many new orally administered agents to treat type 2 diabetes. Sulfonylureas and meglitinides stimulate insulin secretion. Metformin has been joined by thiazolidinediones to reduce insulin resistance. Disaccharidase inhibitors slow glucose uptake after a meal. Beta-3 agonists and agents that augment glucagon-like peptide activity are promising new agents in the effort to not only control glucose levels but also restrain weight gain. The future treatment of diabetes will require multiple drugs working in concert to normalize blood glucose.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2004 PMID： 15647714 PMCID： PMC1474831

Source DB: PubMed Journal: MedGenMed ISSN： 1531-0132

38 in total

1. Incidence of lactic acidosis in metformin users.

Authors: M Stang; D K Wysowski; D Butler-Jones
Journal: Diabetes Care Date: 1999-06 Impact factor: 19.112

2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors: D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal: N Engl J Med Date: 1993-09-30 Impact factor: 91.245

3. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

Authors: R A DeFronzo; N Barzilai; D C Simonson
Journal: J Clin Endocrinol Metab Date: 1991-12 Impact factor: 5.958

4. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.

Authors: R F Coniff; J A Shapiro; T B Seaton
Journal: Arch Intern Med Date: 1994-11-14

5. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

Authors: R B Goldberg; D Einhorn; C P Lucas; M S Rendell; P Damsbo; W C Huang; P Strange; R G Brodows
Journal: Diabetes Care Date: 1998-11 Impact factor: 19.112

6. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study.

Authors: D E Singer; D M Nathan; K M Anderson; P W Wilson; J C Evans
Journal: Diabetes Date: 1992-02 Impact factor: 9.461

7. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors:
Journal: Lancet Date: 1998-09-12 Impact factor: 79.321

8. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.

Authors: P Reichard; B Y Nilsson; U Rosenqvist
Journal: N Engl J Med Date: 1993-07-29 Impact factor: 91.245

9. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.

Authors: P S Johnston; R F Coniff; B J Hoogwerf; J V Santiago; F X Pi-Sunyer; A Krol
Journal: Diabetes Care Date: 1994-01 Impact factor: 19.112

10. Effect of a beta 3-adrenergic agonist, BRL35135A, on glucose uptake in rat skeletal muscle in vivo and in vitro.

Authors: H Abe; Y Minokoshi; T Shimazu
Journal: J Endocrinol Date: 1993-12 Impact factor: 4.286

6 in total

Review 1. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.

Authors: Giuseppe Derosa
Journal: Drugs Date: 2010-10-22 Impact factor: 9.546

Review 6. Recent Advances in Astragalus membranaceus Anti-Diabetic Research: Pharmacological Effects of Its Phytochemical Constituents.

Authors: Kojo Agyemang; Lifeng Han; Erwei Liu; Yi Zhang; Tao Wang; Xiumei Gao
Journal: Evid Based Complement Alternat Med Date: 2013-11-17 Impact factor: 2.629